Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess the utility of nintedanib therapy in addition to usual
transplant care in single lung transplant recipients with idiopathic pulmonary fibrosis
(IPF). The investigators hypothesize that in IPF subjects who undergo single lung
transplantation the administration of nintedanib 150 mg twice daily in addition to usual
transplant care will result in better preservation of lung function at 24 months.